Rekvina Labs Ltd
Rekvina Labs Ltd Live Price Chart
Performance
| Previous Close | ₹ 47.83 |
| High | ₹ 48.78 |
| Volume | 786 |
| 52W Range | ₹ 6.75 - ₹ 48.78 |
| Open | ₹ 48.78 |
| Low | ₹ 48.78 |
| Market Cap | ₹ 15.25 Cr |
Rekvina Labs Ltd Technicals
| 20 Day | ₹ 39.670 |
| 50 Day | ₹ 36.414 |
| 100 Day | ₹ 33.852 |
| 200 Day | ₹ 27.765 |
| 20 Day | ₹ 37.113 |
| 50 Day | ₹ 34.591 |
| 100 Day | ₹ 79.298 |
| 200 Day | ₹ 244.217 |
Rekvina Labs Ltd Fundamentals
| ROCE | -104.172 |
| P/E Ratio | -157.350 |
| P/B Ratio | 14.040 |
| Industry P/E | 14.040 |
| Debt to Equity | 51.431 |
| ROE | 20.738 |
| EPS | -0.310 |
| Dividend Yield | 0.000 |
| Book Value | 3.474 |
| Face Value | 5.000 |
Rekvina Labs Ltd Financials
| Particulars | Y202503 | Y202403 | Y202303 | Y202203 | Y202103 |
|---|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0.0038 | 0 | 0 |
| Total Expenses | 0.1371 | 0.0164 | 0.0045 | 0.078881001 | 0.0642 |
| Profit After Tax | -0.1371 | -0.0164 | -0.0007 | -0.078881001 | -0.0642 |
Rekvina Labs Ltd Shareholding Pattern
| Promoter Holdings | 77.000 % |
| FIIs | 0.000 % |
| DIIs | 0.000 % |
| MutualFund | 0.000 % |
| Retail | 18.965 % |
| Others - | 4.035 % |
About Rekvina Labs Ltd
Rekvina Labs Limited was incorporated on 1st November 1988. From a small domestic company at inception in middle of 80's, Rekvina has grown formidably to be an integrated, Indian pharmaceutical company with sales in excess of Rs 20 Crore. It is registered in England and Wales as a Public Limited Company. The Company is a Quality producer of Pharmaceutical formulations for its customer as per their specific requirements. It provide contract research and manufacturing services to customers. The Company is mainly engaged in manufacturing and marketing of pharmaceutical products. It presently operates into one business segment i.e. Copper Extrusion. The Company had launched a new product 'REKSEAL', a tissue adhesive for wound closure from the market in 1999-2000. Though there was persistent recessionary trend in the pharmaceutical industry there is a decrease in the turnover of the Company which affected the. net worth of the Company adversely. In 2019-20, there was an overall slowdown in the economy. The Company incurred losses over a couple of years. The Company is focusing on strengthening its core business of manufacturing and marketing formulations. Research and Development (R&D) initiatives have been accelerated to improve cost competitiveness and ensure compliance with global regulatory requirements. Cost optimization, efficient resource utilization, and strong management control are being emphasized across all operations. ...
Similar Stocks
| Ambalal Sarabhai Enterprises Ltd Pharmaceuticals | ₹ 43.53 -0.38 (-0.87%) |
| Amrutanjan Health Care Ltd Pharmaceuticals | ₹ 515.05 -1.35 (-0.26%) |
| Astrazeneca Pharma India Ltd Pharmaceuticals | ₹ 7,081.00 -40.1 (-0.56%) |
| Bliss GVS Pharma Ltd Pharmaceuticals | ₹ 587.05 +27.95 (+5%) |
| Abbott India Ltd Pharmaceuticals | ₹ 26,740.00 +361.6 (+1.37%) |
| Cipla Ltd Pharmaceuticals | ₹ 1,418.00 -1.9 (-0.13%) |
FAQs on Rekvina Labs Ltd
1. Can I buy Rekvina Labs Ltd from PL Capital? ›
2. Does Rekvina Labs Ltd pay dividends? ›
3. What is the current share price of Rekvina Labs Ltd ? ›
4. What is the 52-week high and low of Rekvina Labs Ltd ? ›
Start SIP in Rekvina Labs Ltd
Invest systematically in stocks with the
PL Capital app
Are you a new user? Open your account
